Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Quarterly results
Talis Biomedical Corp (TLIS) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/10/2023 8-K Investor presentation, Quarterly results
Docs: "Talis Biomedical Corporation Condensed Balance Sheets June 30, December 31, 2023 2022 Assets Current assets: Cash and cash equivalents $ 98,200 $ 130,191 Restricted cash 1,010 — Accounts receivable, net 532 308 Prepaid expenses and other current assets 2,223 2,783 Total current assets 101,965 133,282 Property and equipment, net 3,539 3,312 Operating lease right-of-use-assets 16,030 30,920 Other long-term assets 1,542 1,776 Total assets $ 123,076 $ 169,290 Liabilities and Stockholders’ Equity Current liabilities: Accounts payable $ 2,491 $ 3,768 Accrued compensation 3,097 4,212 Accrued liabilities 938 989 Operating lease liabilities, current portion 2,736 3,703 Total current liabilities 9,262 12,672 Operating lease liabilities, long-term portion 17,648 29,879 Total liabilities $ 26,910 $ 42...",
"COVID ACCELERATED POC PLATFORM ADOPTION"
08/02/2023 8-K Quarterly results
07/27/2023 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "New Data Presented at the Infectious Disease Society for Obstetrics and Gynecology Annual Meeting Differentiate Talis Biomedical’s Women’s and Sexual Health Product Menu Preliminary data suggest a chlamydia, gonorrhea and trichomonas multiplex test is feasible on a molecular point-of-care test system with time to result in less than 30 minutes Ability to effectively lyse challenging fungal pathogens, including Candida, in under four minutes on Talis One® system positions Company to develop POC vaginal infection panel"
07/24/2023 8-K Quarterly results
07/05/2023 8-K Quarterly results
06/09/2023 8-K Submission of Matters to a Vote of Security Holders  Interactive Data
05/23/2023 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
05/11/2023 8-K Investor presentation, Quarterly results
Docs: "Talis Biomedical Corporation Condensed Balance Sheets March 31 December 31, 2023 2022 Assets Current assets: Cash and cash equivalents $ 112,959 $ 130,191 Restricted cash 1,010 — Accounts receivable, net 127 308 Prepaid expenses and other current assets 1,492 2,783 Total current assets 115,588 133,282 Property and equipment, net 3,634 3,312 Operating lease right-of-use-assets 12,289 30,920 Other long-term assets 1,542 1,776 Total assets $ 133,053 $ 169,290 Liabilities and Stockholders’ Equity Current liabilities: Accounts payable $ 3,871 $ 3,768 Accrued compensation 2,733 4,212 Accrued liabilities 1,614 989 Operating lease liabilities, current portion 2,962 3,703 Total current liabilities 11,180 12,672 Operating lease liabilities, long-term portion 11,749 29,879 Total liabilities $ 22,929 ...",
"COVID ACCELERATED POC PLATFORM ADOPTION"
05/08/2023 8-K Other Events, Financial Statements and Exhibits  Interactive Data
03/10/2023 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
01/25/2023 8-K Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing  Interact...
11/03/2022 8-K Quarterly results
08/12/2022 8-K Other Events  Interactive Data
08/02/2022 8-K Quarterly results
06/10/2022 8-K Quarterly results
06/02/2022 8-K Quarterly results
05/10/2022 8-K Quarterly results
Docs: "Talis Biomedical Corporation Condensed balance sheets March 31, December 31, 2022 2021 Assets Current assets: Cash and cash equivalents $ 187,586 $ 232,545 Accounts receivable, net 2,599 183 Inventory 3,499 — Prepaid expenses and other current assets 7,138 3,387 Total current assets 200,822 236,115 Property and equipment, net 10,765 10,528 Operating lease right-of-use-assets 12,693 12,907 Other long-term assets 6,307 6,278 Total assets $ 230,587 $ 265,828 Liabilities and Stockholders’ Equity Current liabilities: Accounts payable $ 5,263 $ 5,122 Accrued compensation 4,889 6,369 Accrued liabilities 3,496 6,383 Operating lease liabilities, current portion 1,628 1,232 Total current liabilities 15,276 19,106 Operating lease liabilities, long-term portion 12,526 12,745 Total liabilities $ 27,802..."
04/22/2022 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
03/15/2022 8-K Quarterly results
12/09/2021 8-K Quarterly results
11/15/2021 8-K Quarterly results
Docs: "Offer Letter, by and between the Company and Brian Blaser",
"Talis Biomedical Corporation 2021 Inducement Plan",
"Form of Stock Option Grant Notice, Option Agreement and Notice of Exercise under the Talis Biomedical Corporation 2021 Inducement Plan",
"Form of Restricted Stock Unit Award Grant Notice and Award Agreement (Restricted Stock Unit Award) under the Talis Biomedical Corporation 2021 Inducement Plan",
"Talis Biomedical Announces Third Quarter 2021 Financial Results and Business Progress Conference call and webcast today at 4:30pm Eastern/1:30pm Pacific",
"Talis Biomedical Announces Appointment of Brian Blaser as President, Chief Executive Officer and Director Veteran executive previously led Abbott's global diagnostics organization"
11/10/2021 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Talis Biomedical Granted FDA Emergency Use Authorization for COVID-19 Molecular Point-of-Care Test to Detect SARS-CoV-2 Authorized for use in a variety of healthcare and congregate settings, Talis One™ enables lab-quality results without the wait to detect or rule out COVID-19 in less than 30 minutes"
08/31/2021 8-K Quarterly results
08/10/2021 8-K Quarterly results
05/11/2021 8-K Quarterly results
03/18/2021 8-K Quarterly results
03/08/2021 8-K Quarterly results
02/17/2021 8-K Quarterly results

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy